摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

MMV665898

中文名称
——
中文别名
——
英文名称
MMV665898
英文别名
MB1_E_665898A-3;N-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-3,4,5-trimethoxybenzamide;N-[4-(1H-benzimidazol-2-yl)phenyl]-3,4,5-trimethoxybenzamide
MMV665898化学式
CAS
——
化学式
C23H21N3O4
mdl
——
分子量
403.437
InChiKey
AIDJWZIOMBFHID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    85.5
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    4-(1H-苯并咪唑-2-基)苯胺3,4,5-三甲氧基苯甲酰氯N,N-二甲基甲酰胺 为溶剂, 反应 24.0h, 以20%的产率得到MMV665898
    参考文献:
    名称:
    Benzimidazole-2-Phenyl-Carboxamides as Dual-Target Inhibitors of BVDV Entry and Replication
    摘要:
    牛病毒性腹泻病毒(BVDV)又称 Pestivirus A,主要引起牛的严重感染,也可引起猪、绵羊和山羊的严重感染,每年给农业农场造成巨大的经济损失。实际上,通过隔离持续感染的动物和接种疫苗可以控制感染,但目前还没有抗病毒药物可以控制 BVDV 在农场的传播。BVDV 利用包膜蛋白 E2 与宿主细胞结合,而这种蛋白直到最近才成为强效抗病毒药物研究的目标。相比之下,RdRp 在过去几十年中已被几类化合物成功抑制。作为持久抗病毒研究议程的一部分,我们设计了一系列新的衍生物,这些衍生物是通过对以前报道过的抗 BVDV 化合物中的主要支架进行同位取代而产生的。在这里,我们对新化合物进行了表征和测试,结果表明其中几种化合物对 BVDV 具有强效和选择性活性。利用加药时间测定法对其作用机制进行了深入研究,并利用对接模拟对结果进行了验证。
    DOI:
    10.3390/v14061300
点击查看最新优质反应信息

文献信息

  • Sirtuin modulating compounds
    申请人:Nunes J. Joseph
    公开号:US20070037809A1
    公开(公告)日:2007-02-15
    Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命,并治疗和/或预防各种疾病和疾病,包括与衰老或应激有关的疾病或疾病,糖尿病,肥胖症,神经退行性疾病,心血管疾病,血液凝块性疾病,炎症,癌症和/或红斑病,以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。
  • SIRTUIN MODULATING COMPOUNDS
    申请人:Nunes Joseph J.
    公开号:US20120197013A1
    公开(公告)日:2012-08-02
    Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本文提供了一种新颖的调节沉默信息调节因子(sirtuin)的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命,并用于治疗和/或预防多种疾病和障碍,包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红,以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
  • Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
    申请人:Sirtris Pharmaceuticals, Inc.
    公开号:EP2388263A1
    公开(公告)日:2011-11-23
    Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本文提供了新型sirtuin调节化合物及其使用方法。sirtuin调节化合物可用于延长细胞寿命,治疗和/或预防多种疾病和失调,包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调,以及可从线粒体活性增强中获益的疾病或失调。此外,还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。
  • Thiazolopyridine derivatives as sirtuin-modulators
    申请人:Sirtris Pharmaceuticals, Inc.
    公开号:EP2468752A1
    公开(公告)日:2012-06-27
    Provided herein are novel sirtuin-modulating compounds (XII) and (XIII). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本文提供的是新型 sirtuin 调节化合物 (XII) 和 (XIII)。sirtuin调节化合物可用于延长细胞寿命,治疗和/或预防多种疾病和失调,包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调,以及可从线粒体活性增强中获益的疾病或失调。此外,还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。
  • IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS
    申请人:Sirtris Pharmaceuticals, Inc.
    公开号:EP1910362B1
    公开(公告)日:2012-10-17
查看更多